The University of Tennessee Medical Center is an academic medical center located in Knoxville, Tennessee and serves as a referral center for East Tennessee and regions in Kentucky and North Carolina. The University of Tennessee Graduate School of Medicine oversees residency and medical student education at UTMC.

There are 685 beds in University of Tennessee Medical Center.

During the past decade, University of Tennessee Medical Center conducted 83 clinical trials. In the 10-year time frame, 83 clinical trials started and 37 clinical trials were completed, i.e. on average, 44.6% percent of trials that started reached the finish line to date. In the past 5 years, 33 clinical trials started and 28 clinical trials were completed. i.e. 84.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "University of Tennessee Medical Center" #1 sponsor was "Pfizer" with 7 trials, followed by "Eli Lilly and Company" with 6 trials sponsored, "University of Tennessee Graduate School of Medicine" with 6 trials sponsored, "University of Tennessee" with 5 trials sponsored and "NewLink Genetics Corporation" with 5 trials sponsored. Other sponsors include 93 different institutions and companies that sponsored additional 78 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "University of Tennessee Medical Center" #1 collaborator was "Merck Sharp & Dohme LLC" with 4 trials as a collaborator, "National Cancer Institute (NCI)" with 3 trials as a collaborator, "Celgene Corporation" with 2 trials as a collaborator, "Janssen Research & Development, LLC" with 2 trials as a collaborator and "Medivation, Inc." with 2 trials as a collaborator. Other collaborators include 59 different institutions and companies that were collaborators in the rest 68 trials.

According to Clinical.Site data, the most researched conditions in "University of Tennessee Medical Center" are "Melanoma" (8 trials), "Breast Neoplasms" (4 trials), "Cystic Fibrosis" (4 trials), "Breast Cancer" (3 trials) and "Metastatic Melanoma" (3 trials). Many other conditions were trialed in "University of Tennessee Medical Center" in a lesser frequency.

Most popular intervention types in "University of Tennessee Medical Center" are "Drug" (90 trials), "Biological" (18 trials), "Device" (11 trials), "Other" (10 trials) and "Procedure" (7 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (19 trials), "Pembrolizumab" (6 trials), "Gemcitabine" (5 trials), "Docetaxel" (4 trials) and "Abemaciclib" (3 trials). Other intervention names were less common.

The vast majority of trials in "University of Tennessee Medical Center" are 108 trials for "All" genders, 15 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "University of Tennessee Medical Center". undefined are not yet recruiting, 23 are recruiting, 20 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 61 completed trials in University of Tennessee Medical Center, undefined suspended trials, and 18 terminated clinical trials to date.

Out of the total trials that were conducted in University of Tennessee Medical Center, 11 "Phase 1" clinical trials were conducted, 33 "Phase 2" clinical trials and 54 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 8 trials, and there were also 13 trials that are defined as “Not Applicable".

University of Tennessee Medical Center has several departments that took part in Clinical trials: "U.T. Medical Center Cancer Institute" - 32 trials, "Heartland Medical, PC" - 6 trials, "Knoxville Gynecologic Cancer Specialists PC" - 5 trials, "University of Tennessee Medical Center - Adult Cystic Fibrosis Clinic" - 4 trials, "University of Tennessee -University Vascular Surgeons" - 2 trials